No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
www.cosmopharma.comNo one on the platform currently holds COPN.SW.
No tracked institution reports a position in COPN.SW as of their last filing.
No one on the platform has traded COPN.SW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -60.7% | 11.5% | ||||
| Profit Margin % | -3.5% | 18.3% | -0.8% | |||
| Free Cash Flow Margin % | -15.1% | 19.0% | -2.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $106M | +3.8% | $0.12 | $0.04–$0.20 | — | 5 |
| 2027 | $143M | +34.8% | $1.36 | $0.17–$3.48 | — | 4 |
| 2028 | $185M | +29.0% | $2.11 | $1.53–$3.41 | — | 2 |
| 2029 | $239M | +29.5% | $3.28 | $2.37–$5.29 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $-0.03 | $-0.26 | -823.2% |
| 2026-03-09 | $-0.02 | $-0.09 | -400.1% |
| 2025-03-06 | $1.45 | $3.28 | +126.2% |
| -4.00% |
| $1.3B |
| — |
| KURN.SWKuros Biosciences AG | $17.05 | -4.43% | $672M | — |
| MED.SWMedartis Holding AG | $82.90 | -1.19% | $1.0B | — |
Source: Financial Modeling Prep · peers by sector/industry